ALVO Alvotech
Data as of close
Healthcare · Biological Products, (No Diagnostic Substances)
Alvotech (ALVO) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $1.5 billion. Shares last traded at $4.68, 28.3% below their 52-week high. Over the past year the stock is down 6.8%.
* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Biological Products, (No Diagnostic Substances) peers
ALVO vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Data as of close
| AMGN | Amgen | $258.7B | 27.55 | 6.65 | 24.1% | +3.81% |
| GILD | Gilead Sciences | $216.4B | — | 6.98 | -12.5% | +4.15% |
| MRNA | Moderna | $103.1B | — | — | — | +13.05% |
| RVMD | Revolution Medicines, Inc. | $43.2B | — | — | — | +2.71% |
| BIIB | Biogen | $37.6B | 108.29 | 3.65 | 3.4% | +2.23% |
| EXEL | Exelixis, Inc. | $17.8B | 20.06 | 7.11 | 35.5% | +0.58% |
| NBIX | Neurocrine Biosciences Inc | $16.8B | 23.92 | 4.54 | 19.0% | +0.70% |
| HALO | Halozyme Therapeutics, Inc. | $14.8B | 35.78 | 8.89 | 24.9% | +1.37% |
| KYMR | Kymera Therapeutics, Inc. | $11.6B | — | — | — | +7.18% |
| TECH | Bio-Techne | $11.4B | 62.82 | 9.40 | 15.0% | +0.10% |
| RGEN | Repligen Corp | $11.4B | — | 14.14 | -1.5% | -0.08% |
| QGEN | Qiagen N.V. | $11.0B | 25.94 | 5.27 | 20.3% | +0.85% |
| PCVX | Vaxcyte, Inc. | $10.4B | — | — | — | +7.89% |
| IBRX | Immunitybio, Inc. | $9.5B | — | — | — | +7.59% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.